The US Food and Drug Administration (USFDA) has completed an inspection at Zydus Cadila’s manufacturing facility in Ankleshwar, Gujarat, with three observations. The inspection was conducted from February 13 to February 17, 2023. Although the company has not provided detailed information about the observations, it has stated that they are not related to data integrity or repeat observations from previous inspections.<\/p>\n
The Ankleshwar plant is a key manufacturing facility for Zydus Cadila, producing a range of pharmaceutical products, including injectables, oral solids, and topical formulations. The USFDA inspection is a critical step in ensuring compliance with regulatory requirements for products exported to the US market. The observations made by the USFDA are considered minor, and the company is expected to respond to them within a specified timeframe.<\/p>\n
Zydus Cadila has a history of USFDA inspections at its various manufacturing facilities. In 2020, the company’s Moraiya facility received a warning letter from the USFDA, citing several observations related to quality control and manufacturing practices. However, the company has since taken corrective actions and has been working to improve its compliance with regulatory requirements.<\/p>\n
The outcome of the recent inspection at the Ankleshwar plant is seen as a positive development for Zydus Cadila, as it indicates that the company is on the right track in terms of compliance with USFDA regulations. The company’s management has stated that it is committed to maintaining high standards of quality and compliance at all its manufacturing facilities.<\/p>\n
The inspection outcome is also significant for the Indian pharmaceutical industry as a whole, as it demonstrates the country’s ability to produce high-quality pharmaceutical products that meet international regulatory standards. India is a major player in the global pharmaceutical industry, with many companies exporting products to the US and other countries.<\/p>\n
In conclusion, the USFDA’s inspection at Zydus Cadila’s Ankleshwar plant with three observations is a positive development for the company and the Indian pharmaceutical industry. While the observations are minor, the company will need to respond to them promptly to ensure compliance with regulatory requirements. The inspection outcome highlights the importance of maintaining high standards of quality and compliance in the pharmaceutical industry, and Zydus Cadila’s commitment to these principles is expected to support its growth and success in the global market.<\/p>\n","protected":false},"excerpt":{"rendered":"
The US Food and Drug Administration (USFDA) has completed an inspection at Zydus Cadila’s manufacturing facility in Ankleshwar, Gujarat, with three observations. The inspection was conducted from February 13 to February 17, 2023. Although the company has not provided detailed information about the observations, it has stated that they are not related to data integrity […]<\/p>\n","protected":false},"author":1,"featured_media":88150,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2,19],"tags":[],"class_list":["post-89847","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma","category-zydus"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89794,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/13\/dr-reddys-laboratories-has-been-issued-a-pre-approval-inspection-letter-from-the-usfda-for-its-biologics-facility-located-in-hyderabad\/","url_meta":{"origin":89847,"position":0},"title":"Dr. Reddy’s Laboratories has been issued a pre-approval inspection letter from the USFDA for its biologics facility located in Hyderabad.","author":"Team Small News","date":"January 13, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89737,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/02\/usfda-deals-a-blow-to-dr-reddys-biosimilar-denosumab-avt03-following-an-inspection-of-the-manufacturing-facility\/","url_meta":{"origin":89847,"position":1},"title":"USFDA deals a blow to Dr Reddy’s biosimilar denosumab AVT03 following an inspection of the manufacturing facility.","author":"Team Small News","date":"January 2, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has faced a setback in its efforts to bring its denosumab biosimilar, AVT03, to the US market. The US Food and Drug Administration (USFDA) has issued a warning letter to the company after conducting an inspection of its manufacturing facility. The inspection revealed several issues with the\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89862,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/26\/several-major-indian-pharmaceutical-companies-including-sun-pharma-cipla-zydus-and-graviti-have-issued-recalls-for-certain-medications-in-the-united-states-market\/","url_meta":{"origin":89847,"position":2},"title":"Several major Indian pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti, have issued recalls for certain medications in the United States market.","author":"Team Small News","date":"January 26, 2026","format":false,"excerpt":"Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems with impurities, quality control, and production processes. Sun Pharma is recalling over 24,000\u2026","rel":"","context":"In "Cipla"","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89869,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/27\/zydus-lifesciences-introduces-indias-first-biosimilar-version-of-nivolumab-a-global-breakthrough\/","url_meta":{"origin":89847,"position":3},"title":"Zydus Lifesciences introduces India’s first biosimilar version of Nivolumab, a global breakthrough.","author":"Team Small News","date":"January 27, 2026","format":false,"excerpt":"Zydus Lifesciences, a leading life sciences company, has launched the world's first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in the field of Immuno-Oncology. Tishtha will be available in two dosage strengths, 100\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89854,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/25\/bengaluru-to-host-zydus-pinkathon-after-a-7-year-hiatus\/","url_meta":{"origin":89847,"position":4},"title":"Bengaluru to host Zydus Pinkathon after a 7-year hiatus","author":"Team Small News","date":"January 25, 2026","format":false,"excerpt":"The Zydus Pinkathon, a prominent women's running event, is set to return to Bengaluru on January 25, marking its eighth edition in the city after a seven-year hiatus. With an expected participation of over 5,000 women, the event aims to promote fitness and community engagement among women of all age\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89789,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/delhi-high-court-grants-permission-to-zydus-to-market-nivolumab-biosimilar-a-cancer-treatment-drug-in-india\/","url_meta":{"origin":89847,"position":5},"title":"Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a previous order that had restrained the launch\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89847"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89847\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88150"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}